Influence of xanthotoxin (8-methoxypsoralen) on the anticonvulsant activity of various novel antiepileptic drugs against maximal electroshock-induced seizures in mice

Fitoterapia

Volumn 115, Issue , 2016, Pages 86-91

  Zagaja, Mirosław ^a   Andres Mach, Marta ^a   Patrzylas, Paweł ^b,c   Pyrka, Daniel ^b   Szpringer, Monika ^d   Florek Łuszczki, Magdalena ^a   Żółkowska, Dorota ^e   Skalicka Woźniak, Krystyna ^b   Łuszczki, Jarogniew J ^a,b  

^a INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c JOHN PAUL II CATHOLIC UNIVERSITY OF LUBLIN   (Poland)

^d JAN KOCHANOWSKI UNIVERSITY   (Poland)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Coumarins; Maximal electroshock induced seizure test; Novel antiepileptic drugs; Pharmacodynamic interaction; Xanthotoxin

Indexed keywords

LACOSAMIDE; LAMOTRIGINE; METHOXSALEN; OXCARBAZEPINE; PREGABALIN; TOPIRAMATE; ACETAMIDE DERIVATIVE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; FRUCTOSE; TRIAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CHIMNEY TEST; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG POTENTIATION; ELECTRODE; ELECTROSHOCK-INDUCED CONVULSION; GRIP STRENGTH TEST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOTOR COORDINATION; MOUSE; MUSCLE STRENGTH; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; STEP-THROUGH PASSIVE AVOIDANCE TEST; STIMULUS; SWISS WEBSTER MOUSE; ANALOGS AND DERIVATIVES; ANIMAL; ELECTROSHOCK; SEIZURES;

ACETAMIDES; ANIMALS; ANTICONVULSANTS; CARBAMAZEPINE; DRUG SYNERGISM; ELECTROSHOCK; FRUCTOSE; MALE; METHOXSALEN; MICE; PREGABALIN; SEIZURES; TRIAZINES;

EID: 84989873719     PISSN: 0367326X     EISSN: 18736971     Source Type: Journal    
DOI: 10.1016/j.fitote.2016.09.020     Document Type: Article

References (47)

1. [1] Zhu, H.L., Wan, J.B., Wang, Y.T., Li, B.C., Xiang, C., He, J., Li, P., Medicinal compounds with antiepileptic/anticonvulsant activities. Epilepsia 55 (2014), 3–16.
2. [2] Kozak, M., Sobczak, P., Żukiewicz-Sobczak, W., Health properties of selected herbal plants. Health Probl. Civil. 10 (2016), 64–70.
3. [3] Gebauer, M., Synthesis and structure–activity relationships of novel warfarin derivatives. Bioorg. Med. Chem. 15 (2007), 2414–2420.
4. [4] Eisenbrand, G., Toxicological assessment of furocoumarins in foodstuffs. Mol. Nutr. Food Res. 51 (2007), 367–373.
5. [5] Tsassi, V.B., Hussain, H., Meffo, B.Y., Kouam, S.F., Dongo, E., Schulz, B., Greene, I.R., Krohn, K., Antimicrobial coumarins from the stem bark of Afraegle paniculata. Nat. Prod. Commun. 5 (2010), 559–561.
6. [6] Kostova, I., Synthetic and natural coumarins as cytotoxic agents. Curr. Med. Chem. Anticancer Agents 5 (2005), 29–46.
7. [7] Piao, X.L., Park, I.H., Baek, S.H., Kim, H.Y., Park, M.K., Park, J.H., Antioxidative activity of furanocoumarins isolated from Angelicae dahuricae. J. Ethnopharmacol. 93 (2004), 243–246.
8. [8] Epifano, F., Molinaro, G., Genovese, S., Ngomba, R.T., Nicoletti, F., Curini, M., Neuroprotective effect of prenyloxycoumarins from edible vegetables. Neurosci. Lett. 443 (2008), 57–60.
9. [9] Zic, J.A., The treatment of cutaneous T-cell lymphoma with photopheresis. Dermatol. Ther. 16 (2003), 337–346.
10. [10] McNeely, W., Goa, K.L., 5-methoxypsoralen. Drugs 56 (1998), 667–690.
11. [11] Sellers, E.M., Kaplan, H.L., Tyndale, R.F., Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin. Pharmacol. Ther. 68 (2000), 35–43.
12. [12] Budzynska, B., Skalicka-Wozniak, K., Kruk-Slomka, M., Wydrzynska-Kuzma, M., Biala, G., In vivo modulation of the behavioral effects of nicotine by the coumarins xanthotoxin, bergapten, and umbelliferone. Psychopharmacology 233 (2016), 2289–2300.
13. [13] Tian, W., Cai, J., Xu, Y., Luo, X., Zhang, J., Zhang, Z., Zhang, Q., Wang, X., Hu, L., Lin, G., Determination of xanthotoxin using a liquid chromatography-mass spectrometry and its application to pharmacokinetics and tissue distribution model in rat. Int. J. Clin. Exp. Med. 8 (2015), 15164–15172.
14. [14] Łuszczki, J.J., Glowniak, K., Czuczwar, S.J., Time–course and dose–response relationships of imperatorin in the mouse maximal electroshock seizure threshold model. Neurosci. Res. 59 (2007), 18–22.
15. [15] Tosun, F., Kizilay, C.A., Erol, K., Kilic, F.S., Kurkcuoglu, M., Baser, K.H.C., Anticonvulsant activity of furanocoumarins and the essential oil obtained from the fruits of Heracleum crenatifolium. Food Chem. 107 (2008), 990–993.
16. [16] Łuszczki, J.J., Andres-Mach, M., Cisowski, W., Mazol, I., Glowniak, K., Czuczwar, S.J., Osthole suppresses seizures in the mouse maximal electroshock seizure model. Eur. J. Pharmacol. 607 (2009), 107–109.
17. [17] Skalicka-Woźniak, K., Zagaja, M., Głowniak, K., Łuszczki, J.J., Purification and anticonvulsant activity of xanthotoxin (8-methoxypsoralen). Cent. Eur. J. Biol. 9 (2014), 431–436.
18. [18] Łuszczki, J.J., Andres-Mach, M., Glensk, M., Skalicka-Wozniak, K., Anticonvulsant effects of four linear furanocoumarins, bergapten, imperatorin, oxypeucedanin, and xanthotoxin, in the mouse maximal electroshock-induced seizure model: a comparative study. Pharmacol. Rep. 62 (2010), 1231–1236.
19. [19] Zagaja, M., Andres-Mach, M., Skalicka-Woźniak, K., Rękas, A.R., Kondrat-Wróbel, M.W., Gleńsk, M., Łuszczki, J.J., Assessment of the combined treatment with umbelliferone and four classical antiepileptic drugs against maximal electroshock-induced seizures in mice. Pharmacology 96 (2015), 175–180.
20. [20] Łuszczki, J.J., Glowniak, K., Czuczwar, S.J., Imperatorin enhances the protective activity of conventional antiepileptic drugs against maximal electroshock-induced seizures in mice. Eur. J. Pharmacol. 574 (2007), 133–139.
21. [21] Łuszczki, J.J., Wojda, E., Raszewski, G., Glowniak, K., Czuczwar, S.J., Influence of imperatorin on the anticonvulsant and acute adverse-effect potential of lamotrigine in maximal electroshock-induced seizures and chimney test in mice. Pharmacol. Rep. 60 (2008), 566–573.
22. [22] Zagaja, M., Pyrka, D., Skalicka-Wozniak, K., Glowniak, K., Florek-Łuszczki, M., Glensk, M., Łuszczki, J.J., Effect of xanthotoxin (8-methoxypsoralen) on the anticonvulsant activity of classical antiepileptic drugs against maximal electroshock-induced seizures in mice. Fitoterapia 105 (2015), 1–6.
23. [23] Löscher, W., Fassbender, C.P., Nolting, B., The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res. 8 (1991), 79–94.
24. [24] Łuszczki, J.J., Wlaź, A., Karwan, S., Florek-Luszczki, M., Czuczwar, S.J., Effects of WIN 55,212-2 mesylate on the anticonvulsant action of lamotrigine, oxcarbazepine, pregabalin and topiramate against maximal electroshock-induced seizures in mice. Eur. J. Pharmacol. 720 (2013), 247–254.
25. [25] Florek-Łuszczki, M., Wlaz, A., Zagaja, M., Andres-Mach, M., Kondrat-Wrobel, M.W., Łuszczki, J.J., Effects of WIN 55,212-2 (a synthetic cannabinoid CB1 and CB2 receptor agonist) on the anticonvulsant activity of various novel antiepileptic drugs against 6 Hz-induced psychomotor seizures in mice. Pharmacol. Biochem. Behav. 130 (2015), 53–58.
26. [26] Litchfield, J.T. Jr., Wilcoxon, F., A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96 (1949), 99–113.
27. [27] Kondrat-Wróbel, M.W., Łuszczki, J.J., Interaction of three-drug combination of lacosamide, carbamazepine and phenobarbital in the mouse maximal electroshock-induced seizure model – an isobolographic analysis. Health Probl. Civil. 10 (2016), 55–61.
28. [28] Boissier, J.R., Tardy, J., Diverres, J.C., Une nouvelle methode simple pour explorer l'action tranquilisante: le test de la cheminee. Med. Exp. (Basel) 3 (1960), 81–84.
29. [29] Florek-Łuszczki, M., Zagaja, M., Łuszczki, J.J., Influence of WIN 55,212-2 on the anticonvulsant and acute neurotoxic potential of clobazam and lacosamide in the maximal electroshock-induced seizure model and chimney test in mice. Epilepsy Res. 108 (2014), 1728–1733.
30. [30] Schmidt, D., Elger, C.E., What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?. Epilepsy Behav. 5 (2004), 627–635.
31. [31] Schachter, S.C., Tricyclic anticonvulsants: mechanisms of action. Epilepsy Behav. 3 (2002), 7–8.
32. [32] Stefani, A., Spadoni, F., Bernardi, G., Voltage-activated calcium channels: targets of antiepileptic drug therapy?. Epilepsia 38 (1997), 959–965.
33. [33] Calabresi, P., De Murtas, M., Stefani, A., Pisani, A., Sancesario, G., Mercuri, N.B., Bernardi, G., Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. I. Modulation of corticostriatal synaptic transmission. Epilepsia 36 (1995), 990–996.
34. [34] McLean, M.J., Oxcarbazepine: mechanisms of action. Levy, R.H., Mattson, R.H., Meldrum, B.S., Perucca, E., (eds.) Antiepileptic Drugs, fifth ed., 2002, Lippincott Williams & Wilkins, Philadelphia, 451–458.
35. [35] Stefani, A., Pisani, A., De Murtas, M., Mercuri, N.B., Marciani, M.G., Calabresi, P., Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents. Epilepsia 36 (1995), 997–1002.
36. [36] Waldmeier, P.C., Martin, P., Stöcklin, K., Portet, C., Schmutz, M., Effect of carbamazepine, oxcarbazepine and lamotrigine on the increase in extracellular glutamate elicited by veratridine in rat cortex and striatum. Naunyn Schmiedeberg's Arch. Pharmacol. 354 (1996), 164–172.
37. [37] Errington, A.C., Stöhr, T., Heers, C., Lees, G., The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol. Pharmacol. 73 (2008), 157–169.
38. [38] Curia, G., Biagini, G., Perucca, E., Avoli, M., Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs 23 (2009), 555–568.
39. [39] Errington, A.C., Coyne, L., Stöhr, T., Selve, N., Lees, G., Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 50 (2006), 1016–1029.
40. [40] Qin, N., Yagel, S., Momplaisir, M.L., Codd, E.E., D'Andrea, M.R., Molecular cloning and characterization of the human voltage-gated calcium channel alpha(2)delta-4 subunit. Mol. Pharmacol. 62 (2002), 485–496.
41. [41] Taylor, C.P., Angelotti, T., Fauman, E., Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 73 (2007), 137–150.
42. [42] Macdonald, R.L., Rogawski, M.A., Cellular effects of antiepileptic drugs. Engel, J., Pedley, T.A., (eds.) Epilepsy: A Comprehensive Textbook, 2nd edn, 2008, Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, 1433–1445.
43. [43] Szewczyk, A., De Weille, J.R., Lazdunski, M., 8-Methoxypsoralen blocks ATP-sensitive potassium channels and stimulates insulin release. Eur. J. Pharmacol. 216 (1992), 323–326.
44. [44] Isoldi, M.C., Pereira, E.A., Visconti, M.A., Castrucci, A.M., The role of calcium, calcium activated K + channels, and tyrosine/kinase in psoralen-evoked responses in human melanoma cells. Braz. J. Med. Biol. Res. 37 (2004), 559–568.
45. [45] Jensen, B.S., Strobaek, D., Olesen, S.P., Christophersen, P., The Ca2 +-activated K + channel of intermediate conductance: a molecular target for novel treatments?. Curr. Drug Targets 2 (2001), 401–422.
46. [46] Postea, O., Biel, M., Exploring HCN channels as novel drug targets. Nat. Rev. Drug Discov. 10 (2011), 903–914.
47. [47] Grunze, H., von Wegerer, J., Greene, R.W., Walden, J., Modulation of calcium and potassium currents by lamotrigine. Neuropsychobiology 38 (1998), 131–138.